Free Trial
NASDAQ:SRTS

Sensus Healthcare (SRTS) Stock Price, News & Analysis

$5.80
-0.19 (-3.17%)
(As of 07/17/2024 ET)
Today's Range
$5.58
$5.85
50-Day Range
$3.81
$6.42
52-Week Range
$1.79
$6.55
Volume
209,449 shs
Average Volume
343,648 shs
Market Capitalization
$95.06 million
P/E Ratio
20.00
Dividend Yield
N/A
Price Target
$10.00

Sensus Healthcare MarketRank™ Stock Analysis

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
72.4% Upside
$10.00 Price Target
Short Interest
Healthy
3.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Sensus Healthcare in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$123,416 Sold Last Quarter
Proj. Earnings Growth
70.00%
From $0.30 to $0.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.98 out of 5 stars

Medical Sector

188th out of 914 stocks

Surgical & Medical Instruments Industry

23rd out of 99 stocks

SRTS stock logo

About Sensus Healthcare Stock (NASDAQ:SRTS)

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

SRTS Stock Price History

SRTS Stock News Headlines

I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
See More Headlines
Receive SRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensus Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/17/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:SRTS
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+72.4%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$490,000.00
Pretax Margin
20.37%

Debt

Sales & Book Value

Annual Sales
$24.41 million
Cash Flow
$0.06 per share
Book Value
$2.98 per share

Miscellaneous

Free Float
14,573,000
Market Cap
$95.06 million
Optionable
Optionable
Beta
1.00
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Joseph C. SardanoMr. Joseph C. Sardano (Age 71)
    Co-Founder, Chairman & CEO
    Comp: $754.43k
  • Mr. Michael J. Sardano (Age 35)
    President, General Counsel, Corporate Secretary & Director
    Comp: $404.74k
  • Mr. Javier Rampolla (Age 51)
    Chief Financial Officer
    Comp: $439.14k
  • Ms. Magdalena Martinez (Age 34)
    Chief Operating Officer
  • Mr. Emiliano Sosa (Age 46)
    Chief Technology Officer
  • Ms. Stephanie Tipton
    Vice President of Marketing
  • Dr. Mark S. Nestor
    Medical Director & Member of Medical Advisory Board
  • Dr. Clay Jefferies Cockerell (Age 67)
    Clinical Director & Member of Medical Advisory Board

SRTS Stock Analysis - Frequently Asked Questions

How have SRTS shares performed this year?

Sensus Healthcare's stock was trading at $2.36 at the start of the year. Since then, SRTS shares have increased by 145.8% and is now trading at $5.80.
View the best growth stocks for 2024 here
.

How were Sensus Healthcare's earnings last quarter?

Sensus Healthcare, Inc. (NASDAQ:SRTS) announced its quarterly earnings results on Thursday, May, 9th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.18. The firm had revenue of $10.66 million for the quarter, compared to analysts' expectations of $4.33 million. Sensus Healthcare had a trailing twelve-month return on equity of 9.76% and a net margin of 14.70%.

When did Sensus Healthcare IPO?

Sensus Healthcare (SRTS) raised $20 million in an initial public offering on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

How do I buy shares of Sensus Healthcare?

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sensus Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX) and Vaxart (VXRT).

This page (NASDAQ:SRTS) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners